Iconovo AB (publ) (STO:ICO)

Sweden · Delayed Price · Currency is SEK

1.205

+0.010 (0.84%)

Apr 29, 2026, 9:00 AM CET

-11.72% (1Y)

Market Cap	114.93M
Revenue (ttm)	13.82M
Net Income (ttm)	-40.29M
Shares Out	96.17M
EPS (ttm)	-0.76
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	414
Average Volume	106,012
Open	1.205
Previous Close	1.195
Day's Range	1.205 - 1.205
52-Week Range	0.906 - 2.790
Beta	0.34
RSI	55.68
Earnings Date	Apr 24, 2026

About Iconovo AB

Iconovo AB (publ) develops inhaled medicinal products in Sweden. The company offers ICOres, a multi-dose dry powder inhaler; ICOcap, a capsule based dry powder inhaler; ICOone, a single-dose disposable dry powder inhaler; and ICOpre, a pre-metered dry powder inhaler; and ICOone nasal single-dose dry powder inhaler for nasal use. It serves generic companies. The company has a collaboration agreement with Lonza to develop spray-dried formulations of an intranasal biologic drug; and agreement with Kiox Pharma to develop an inhalable treatment for ... [Read more]

Industry Medical Devices

Sector Healthcare

Founded 2013

Employees 13

Stock Exchange Nasdaq Stockholm

Ticker Symbol ICO

Full Company Profile

Financial Performance

In 2025, Iconovo AB's revenue was 14.53 million, a decrease of -39.46% compared to the previous year's 24.00 million. Losses were -43.36 million, 5.41% more than in 2024.

Financial Statements

News

Iconovo AB Transcript: DNB Carnegie Healthcare Seminar 2026

Revised summary: The company is shifting from a tech platform to monetizing a diverse pipeline of inhaled medicines, including generics and biologics. Regulatory changes and a patent cliff offer market opportunities. Key projects are in licensing and preclinical stages, with partnerships and funding supporting full pharma operations and long-term value.

7 weeks ago - Transcripts

Iconovo AB Earnings Call Transcript: Q3 2025

Major cost reductions and a shift to a commercial focus defined the quarter, with progress on key projects including EcoPre, EcoRes, and intranasal semaglutide. Regulatory changes have improved prospects for generics, and new board members are driving unified strategic direction.

6 months ago - Transcripts

Iconovo AB Transcript: Investor Update

A fully guaranteed SEK 36.6 million rights issue will fund commercialization of inhalation platforms, with a leaner organization and significant cost savings. Focus areas include SymbiCort and Ellipta generics, and intranasal semaglutide, targeting large global markets and aiming for key licensing deals in the next two years.

1 year ago - Transcripts

Iconovo AB Transcript: CMD 2021

5 years ago - Transcripts